Benzinga's M&A Chatter for Thursday September 6, 2012

The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday September 6, 2012: Realty Income to Acquire American Realty Capital Trust in $2.95B Deal The Deal:
Realty Income Corporation O and American Realty Capital Trust ARCT, announced Thursday that they have signed a definitive agreement under which Realty Income will acquire all of the outstanding shares of American Realty Capital Trust in a transaction valued at approximately $2.95 billion. Under the terms of the agreement, American Realty Capital Trust shareholders will receive a fixed exchange ratio of 0.2874 Realty Income shares for each share of American Realty Capital Trust common stock that they own. Based on Realty Income's closing stock price of $42.48 on September 5, 2012, this consideration would be equivalent to $12.21 per share. Upon closing of the transaction, American Realty Capital Trust shareholders are expected to own approximately 25.6% of Realty Income's shares. American Realty Capital Trust closed at $12.20 Thursday, a gain of 2.01% on 20 times average volume. Merge Hires Allen & Company to Explore Strategic Alternatives The Strategic Review:
Merge Healthcare MRGE announced Thursday that its Board of Directors has retained Allen & Company to assist in exploring and evaluating a broad range of strategic alternatives, including a sale of the Company. The Company does not intend to comment further regarding the evaluation of strategic alternatives, unless a definitive agreement for a specific transaction is entered into. Merge Healthcare closed at $3.54 Thursday, a gain of 9.94% on 5 times average volume. Hearing Private Equity Chatter in Brocade The Rumor:
Brocade Communications BRCD is attracting private equity interest, according to Deal Reporter. A spokesperson for Brocade declined comment on the report. Brocade closed at $6.17 Thursday, a gain of 1.73%, on twice average volume. MKM Note Says Big Pharma Could Buy Amarin The Note:
A note from MKM Partners says Amarin AMRN could be a takeout target by December in the mid-$20s. AstraZeneca, Bristol, Sanofi, Merck, Lilly and Roche were among the potential buyers mentioned in the note. An Amarin spokesperson was not available for comment. Amarin closed at $14.62 Thursday, a gain of 3.54% on lower than average volume. Hearing Chatter Higher One Sale Talks Suspended The Rumor:
Sale talks involving Higher One Holdings ONE have been suspended, according to Deal Reporter. On August 2nd, Bloomberg reported that Higher One was seeking a buyer and had been in contact with private equity firms. CEO Mark Volchek responded to the report in an 8-K filing: "It is company policy not to respond to rumors or speculation. We remain committed to providing top quality service to our clients and customers in the higher education space." A Higher One spokesperson was not available to comment on Thursday's rumor. Higher One closed at $12.95 Thursday, a gain of 0.54% on average volume.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsShort IdeasRumorsM&AAfter-Hours CenterMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!